Incyte Corporation v. Sun Pharmaceutical Industries, Ltd., No. 25-1162 (Fed. Cir. May 7, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Sun Pharmaceutical Industries, Ltd. and Sun Pharma- ceutical Industries, Inc. (collectively, Sun) appeal an order from the United States District Court for the District of New Jersey granting Incyte Corporation and Incyte Hold- ings Corporation’s (collectively, Incyte) motion for a prelim- inary injunction enjoining Sun from making, using, selling, advertising, or distributing its drug Leqselvi. On April 9, 2025, we issued an order vacating the injunction with an opinion to follow. For the following reasons, we reverse the district court’s order.